Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma
The primary endpoint in trials of perioperative systemic therapy for urothelial carcinoma is 5-year overall survival (OS). A shorter-term endpoint could significantly speed the translation of advances into practice. We hypothesized that disease-free survival (DFS) could be a surrogate endpoint for O...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2013
|
| In: |
World journal of urology
Year: 2013, Jahrgang: 31, Heft: 1, Pages: 5-11 |
| ISSN: | 1433-8726 |
| DOI: | 10.1007/s00345-012-0939-5 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00345-012-0939-5 |
| Verfasserangaben: | Harun Fajkovic, Eugene K. Cha, Evanguelos Xylinas, Michael Rink, Armin Pycha, Christian Seitz, Christian Bolenz, Allison Dunning, Giacomo Novara, Quoc-Dien Trinh, Pierre I. Karakiewicz, Vitaly Margulis, Jay D. Raman, Thomas J. Walton, Shiro Baba, Joaquin Carballido, Wolfgang Otto, Francesco Montorsi, Yair Lotan, Wassim Kassouf, Hans-Martin Fritsche, Karim Bensalah, Richard Zigeuner, Douglas S. Scherr, Guru Sonpavde, Morgan Roupret, Shahrokh F. Shariat |
| Zusammenfassung: | The primary endpoint in trials of perioperative systemic therapy for urothelial carcinoma is 5-year overall survival (OS). A shorter-term endpoint could significantly speed the translation of advances into practice. We hypothesized that disease-free survival (DFS) could be a surrogate endpoint for OS in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy (RNU). |
|---|---|
| Beschreibung: | Gesehen am 31.03.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 1433-8726 |
| DOI: | 10.1007/s00345-012-0939-5 |